Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
The efficacy of an apelin analog in ameliorating the pathophysiology of pulmonary arterial hypertension
EF 2020-21
Résumé
Pulmonary arterial hypertension (PAH) is a rare progressive syndrome in which lung arterial pressures and vascular resistance are elevated, leading to adverse blood vessel remodeling, and right heart failure which is often fatal. Existing treatments are ineffective hence an average survival time of 3 years from time of diagnosis. Studies have shown that the natural hormone, apelin, is downregulated in patients with PAH. Apelin is shown to have beneficial and protective properties for the blood vessels, inducing their relaxation, and promoting stronger heart contraction. Restoring the apelin pathway is promising in reversing blood vessel defects seen in the disease progression of PAH. However, the salutary actions of apelin are limited by its short half-life due to degradation by enzymes. Apelin analogs have been developed that extend their half-life to allow for evasion of degradation. Our project aims to evaluate the efficacy of an apelin analog in ameliorating the impairments seen in PAH using a rat model of PAH. Caged rats will be split into a control or PAH group. For 3 weeks, the control group will be kept in normal air while PAH rats will be kept in low oxygen and subcutaneously injected with a drug that induces lung injury, sugen, weekly. After, all groups will be kept in normal air for 5 weeks and receive daily apelin analog injections within the last 3 weeks. Echocardiography will be used to assess heart function and structure, and artery catheterization will be used to measure ventricular and blood flow parameters. Hearts and lungs will be removed to undergo histological analysis. We predict that apelin analog treatment will improve the cardiac function of rats exposed to sugen and low oxygen, preventing right heart failure while rescuing rat lung function.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449551
Name
Vu Jennie
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The efficacy of an apelin analog in ameliorating the pathophysiology of pulmonary arterial hypertension
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Apelin; Blood Pressure; Cardiac; Hypertension; Lung; Pulmonary; Pulmonary Arterial Hypertension; Right Ventricular Hypertrophy; Treatment; Vasculature
Abstract
Pulmonary arterial hypertension (PAH) is a rare progressive syndrome in which lung arterial pressures and vascular resistance are elevated, leading to adverse blood vessel remodeling, and right heart failure which is often fatal. Existing treatments are ineffective hence an average survival time of 3 years from time of diagnosis. Studies have shown that the natural hormone, apelin, is downregulated in patients with PAH. Apelin is shown to have beneficial and protective properties for the blood vessels, inducing their relaxation, and promoting stronger heart contraction. Restoring the apelin pathway is promising in reversing blood vessel defects seen in the disease progression of PAH. However, the salutary actions of apelin are limited by its short half-life due to degradation by enzymes. Apelin analogs have been developed that extend their half-life to allow for evasion of degradation. Our project aims to evaluate the efficacy of an apelin analog in ameliorating the impairments seen in PAH using a rat model of PAH. Caged rats will be split into a control or PAH group. For 3 weeks, the control group will be kept in normal air while PAH rats will be kept in low oxygen and subcutaneously injected with a drug that induces lung injury, sugen, weekly. After, all groups will be kept in normal air for 5 weeks and receive daily apelin analog injections within the last 3 weeks. Echocardiography will be used to assess heart function and structure, and artery catheterization will be used to measure ventricular and blood flow parameters. Hearts and lungs will be removed to undergo histological analysis. We predict that apelin analog treatment will improve the cardiac function of rats exposed to sugen and low oxygen, preventing right heart failure while rescuing rat lung function.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vu, Jennie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~